T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: Proof of concept

ecancermedicalscience

Volumn 8, Issue , 2014, Pages

  Ingels, Alexandre ^a   Salas, Rafael E Sanchez ^a   Ravery, Vincent ^b   Fromont Hankard, Gaëlle ^c   Validire, Pierre ^a   Patard, Jean Jacques ^d   Pignot, Géraldine ^d   Prapotnich, Dominique ^a   Olivier, Fabien ^e   Galiano, Marc ^a   Barret, Eric ^a   Rozet, Francois ^a   Weber, Nina ^a   Cathelineau, Xavier ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b BICHAT HOSPITAL   (France)

^c CHU BRETONNEAU   (France)

^d BICÊTRE HOSPITAL   (France)

^e ALTRAN TECHNOLOGIES   (France)

Author keywords

Bladder cancer; Immune reaction; Immunohistochemistry; Immunoscore; Markers; Prognosis; Tumor infiltrating lympocytes

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CD3 ANTIBODY; CD8 ANTIBODY; CELL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVOR; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL INFILTRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEASIBILITY STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATHOLOGIST; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL PREDICTION; SYSTEMIC THERAPY; TH1 CELL; TRANSURETHRAL RESECTION; VERY ELDERLY;

EID: 84919914302     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.486     Document Type: Article

References (29)

1. Morales A, Eidinger D and Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 (2) 180-3 PMID: 820877
2. Alexandroff AB et al (1999) BCG immunotherapy of bladder cancer: 20 years on Lancet 353 (9165) 1689-94 DOI: 10.1016/S0140-6736 (98) 07422-4 PMID: 10335805
3. Zlotta AR et al (2000) What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 87 (6) 844-52 DOI: 10.1002/1097-0215 (20000915) 87:6<844::AID-IJC14>3.0. CO;2-5 PMID: 10956396
4. Ponticiello A et al (2004) Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity Respir Med 98 (6) 509-14 DOI: 10.1016/j.rmed.2003.12.003 PMID: 15191035
5. Zuiverloon TCM et al (2012) Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review Eur Urol 61 (1) 128-45 DOI: 10.1016/j.eururo.2011.09.026
6. Bostrom P et al (2010) Staging and staging errors in bladder Cancer 9 2-9
7. May M et al (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications Eur Urol 57 (5) 850-8 DOI: 10.1016/j. eururo.2009.03.052
8. Sharma P et al (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma Proc Natl Acad Sci U S A 104 (10) 3967-72 DOI: 10.1073/pnas.0611618104 PMID: 17360461 PMCID: 1820692
9. Galon J et al (2012) Cancer classification using the Immunoscore: a worldwide task force J Transl Med 10 205 DOI: 10.1186/1479-5876-10-205 PMID: 23034130 PMCID: 3554496
10. Clemente CG et al (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 77 (7) 1303-10 DOI: 10.1002/(SICI) 1097-0142 (19960401) 77:7<1303::AID-CNCR12>3.0. CO;2-5 PMID: 8608507
11. Mackensen A et al (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma Cancer Res 53 (15) 3569-73 PMID: 8339262
12. Alexe G et al (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates Cancer Res 67 (22) 10669-76 DOI: 10.1158/0008-5472. CAN-07-0539 PMID: 18006808
13. Kärjä V et al (2005) Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy Anticancer Res 25 (6 C) 4435-8 PMID: 16334122
14. Richardsen E et al (2008) The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma Histopathology 53 (1) 30-8 DOI: 10.1111/j.1365-2559.2008.03058.x PMID: 18510570
15. Kawai O et al (2008) Predominant infiltration of macrophages and CD8 (+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer Cancer 113 (6) 1387-95 DOI: 10.1002/cncr.23712 PMID: 18671239
16. Galon J (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 (5795) 1960-4 DOI: 10.1126/science.1129139 PMID: 17008531
17. Fridman WH et al (2012) The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 (4) 298-306 DOI: 10.1038/nrc3245 PMID: 22419253
18. Jakse G et al (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45 (5) 539-546 discussion 546 DOI: 10.1016/j.eururo.2003.12.016 PMID: 15082193
19. Brauers A, Buettner R and Jakse G (2001) Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 165 (3) 808-10 DOI: 10.1016/S0022-5347 (05) 66532-9 PMID: 11176474
20. Ploeg M et al (2012) Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy Urol Oncol 30 (3) 247-51 DOI: 10.1016/j.urolonc.2009.12.020
21. Barentsz JO et al (1996) Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT Eur Radiol 6 (2) 129-33 DOI: 10.1007/BF00181125 PMID: 8797968
22. Paik ML et al (2000) Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy J Urol 2000 163 (6) 1693-6 DOI: 10.1016/S0022-5347 (05) 67522-2 PMID: 10799162
23. Barentsz JO et al (1999) MR imaging of the male pelvis Eur Radiol 9 (9) 1722-36 DOI: 10.1007/s003300050916 PMID: 10602944
24. Dorfman RE et al (1991) Upper abdominal lymph nodes: criteria for normal size determined with CT Radiology 180 (2) 319-22 DOI: 10.1148/radiology.180.2.2068292 PMID: 2068292
25. Advanced Bladder Cancer (ABC) Meta-analysis collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 (2) 202-5 discussion 205-6 DOI: 10.1016/j.eururo.2005.04.006 PMID: 15939524
26. Advanced Bladder Cancer (ABC) Meta-analysis collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 (9373) 1927-34 DOI: 10.1016/S0140-6736 (03) 13580-5 PMID: 12801735
27. Winquist E et al (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis J Urol 171 (2 Pt 1) 561-9 DOI: 10.1097/01.ju.0000090967.08622.33 PMID: 14713760
28. Eggermont AM, Spatz A and Robert C (2014) Cutaneous melanoma Lancet 1; 383 (9919) 816-27 DOI: 10.1016/S0140-6736 (13) 60802-8
29. Carthon BC et al (2010) Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 (10) 2861-71 DOI: 10.1158/1078-0432. CCR-10-0569 PMID: 20460488 PMCID: 2919850